← FDA DRUG APPROVALS

FDA ANDA · ANDA075353

DOXAZOSIN MESYLATE

Sponsor: TEVA

APPLICATION
ANDA075353
TYPE
ANDA
ORIGINAL APPROVAL
2001-01-12
LATEST ACTION
2004-02-13
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

DOXAZOSIN MESYLATEDiscontinued
DOXAZOSIN MESYLATE EQ 8MG BASE · TABLET · ORAL
DOXAZOSIN MESYLATEDiscontinued
DOXAZOSIN MESYLATE EQ 2MG BASE · TABLET · ORAL
DOXAZOSIN MESYLATEDiscontinued
DOXAZOSIN MESYLATE EQ 4MG BASE · TABLET · ORAL
DOXAZOSIN MESYLATEDiscontinued
DOXAZOSIN MESYLATE EQ 1MG BASE · TABLET · ORAL

Approval history

2004-02-13Labeling · Supplement 1AP
2001-01-12OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →